Publicacións (25) Publicacións de Marc García Moure

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage

    Molecular Oncology

  3. The emerging field of viroimmunotherapy for pediatric brain tumors

    Neuro-oncology, Vol. 26, Núm. 11, pp. 1981-1993

  4. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas

    Revue Neurologique, Vol. 179, Núm. 5, pp. 475-480

  2. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. DNA-damaging cancer cells to improve virotherapy

    Molecular Therapy - Oncolytics

  2. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  3. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264

  4. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

    Molecular Cancer Therapeutics, Vol. 21, Núm. 3, pp. 471-480

  5. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

  2. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  3. Erratum: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models (Journal for ImmunoTherapy of Cancer (2021) 9 (e002644) DOI: 10.1136/jitc-2021-002644)

    Journal for ImmunoTherapy of Cancer

  4. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

2020

  1. RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases

    Neuro-Oncology Advances, Vol. 2, Núm. 1

2019

  1. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Acta neuropathologica communications, Vol. 7, Núm. 1, pp. 64

  2. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy

    Journal of Proteomics, Vol. 194, pp. 168-178

  3. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models

    Scientific Reports, Vol. 9, Núm. 1

  4. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1